Regulation of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF-A) expression in podocytes

Kidney International

Volumn 66, Issue 4, 2004, Pages 1471-1478

  Datta, Kaustubh ^a   Li, Jinping ^b   Ananth Karumanchi, S ^b   Wang, Enfeng ^b   Rondeau, Eric ^b   Mukhopadhyay, Debabrata ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b NONE

Author keywords

Integrin; Podocyte; VPF VEGF A

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAMININ; LAMININ RECEPTOR; LUCIFERASE; MESSENGER RNA; PROTEIN KINASE C; PROTEIN P300; SCLEROPROTEIN; VASCULOTROPIN; VASCULOTROPIN A; VERY LATE ACTIVATION ANTIGEN 3;

ARTICLE; CELL INTERACTION; CELL LINE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; GLOMERULOPATHY; GLOMERULUS BASEMENT MEMBRANE; GLOMERULUS FILTRATION; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; PODOCYTE; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; WESTERN BLOTTING;

EID: 4644305374     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2004.00910.x     Document Type: Article

References (50)

1. PAVENSTADT H, KRIZ W, KRETZLER M: Cell biology of the glomerular podocyte. Physiol Rev 83:253-307, 2003
2. ABBATE M, ZOJA C, CORNA D, et al: In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 9:1213-1224, 1998
3. DIXON R, BRUNSKILL NJ: Activation of mitogenic pathways by albumin in kidney proximal tubule epithelial cells: Implications for the pathophysiology of proteinuric states. J Am Soc Nephrol 10:1487-1497, 1999
4. RUGGENENTI P, PERNA A, MOSCONI L, et al: Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Kidney Int 53:1209-1216,1998
5. KREIDBERG JA, SYMONS JM: Integrins in kidney development, function, and disease. Am J Physiol Renal Physiol 279:F233-F242, 2000
6. HEMLER ME: Dystroglycan versatility. Cell 97:543-546, 1999
7. COSGROVE D, RODGERS K, MEEHAN D, et al: Integrin alpha1beta1 and transforming growth factor-beta1 play distinct roles in alport glomerular pathogenesis and serve as dual targets for metabolic therapy. Am J Pathol 157:1649-1659, 2000
8. MINER JH: Developmental biology of glomerular basement membrane components. Curr Opin Nephrol Hypertens 7:13-19, 1998
9. ADLER S, CHEN X: Anti-Fx1A antibody recognizes a beta 1-integrin on glomerular epithelial cells and inhibits adhesion and growth. Am J Physiol 262:F770-F776, 1992
10. KORHONEN M, YLANNE J, LAITINEN L, VIRTANEN I: The alpha 1-alpha 6 subunits of integrins are characteristically expressed in distinct segments of developing and adult human nephron. J Cell Biol 111:1245-1254, 1990
11. DEDHAR S, JEWELL K, ROJIANI M, GRAY V: The receptor for the basement membrane glycoprotein entactin is the integrin alpha 3/beta 1. J Biol Chem 267:18908-18914, 1992
12. ELICES MJ, URRY LA, HEMLER ME: Receptor functions for the integrin VLA-3: Fibronectin, collagen, and laminin binding are differentially influenced by Arg-Gly-Asp peptide and by divalent cations. J Cell Biol 112:169-181, 1991
13. MINER JH, Li C: Defective glomerulogenesis in the absence of laminin alpha5 demonstrates a developmental role for the kidney glomerular basement membrane. Dev Biol 217:278-289, 2000
14. KREIDBERG JA, DONOVAN MJ, GOLDSTEIN SL, et al: Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development 122:3537-3547, 1996
15. SIMON M, GRONE HJ, JOHREN O: Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney. Am J Physiol 268:F240-F250, 1995
16. SHULMAN K, ROSEN S, TOGNAZZI K, et al: Expression of vascular permeability factor (VPF/VEGF) is altered in many glomerular diseases. J Am Soc Nephrol 7:661-666, 1996
17. SENGER DR, GALLI SJ, DVORAK AM, et al: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219:983-985, 1983
18. SENGER DR, PERRUZZI CA, FEDER J, DVORAK HF: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. Cancer Res 46:5629-5632, 1986
19. DVORAK HF, DVORAK AM, MANSEAU EJ, et al: Fibrin gel investment associated with line 1 and line 10 solid tumor growth, angiogenesis, and fibroplasia in guinea pigs. Role of cellular immunity, myofibroblasts, microvascular damage, and infarction in line 1 tumor regression. J Natl Cancer Inst 62:1459-1472, 1979
20. DVORAK HF, SIOUSSAT TM, BROWN LF, et al: Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: Concentration in tumor blood vessels. J Exp Med 174:1275-1278, 1991
21. KOCH WJ, HAWES BE, INGLESE J, et al: Cellular expression of the carboxyl terminus of a G protein-coupled receptor kinase attenuates G beta gamma-mediated signaling. J Biol Chem 269:6193-6197, 1994
22. GUIDI AJ, ABU-JAWDEH G, BERSE B, et al: Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. J Natl Cancer Inst 87:1237-1245, 1995
23. LEUNG DW, CACHIANES G, KUANG WJ, et al: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309, 1989
24. ROBERT B, ZHAO X, ABRAHAMSON DR: Coexpression of neuropilin-1, Flk1, and VEGF(164) in developing and mature mouse kidney glomeruli. Am J Physiol Renal Physiol 279:F275-F282, 2000
25. FOSTER RR, HOLE R, ANDERSON K, et al: Functional evidence that vascular endothelial growth factor may act as an autocrine factor on human podocytes. Am J Physiol Renal Physiol 284:F1263-F1273, 2003
26. EREMINA V, SOOD M, HAIGH J, et al: Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. J Clin Invest 111:707-716, 2003
27. MAYNARD SE, MIN JY, MERCHAN J, et al: Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111:649-658, 2003
28. YANG JC, HAWORTH L, SHERRY RM, et al: A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427-434, 2003
29. IRUELA-ARISPE L, GORDON K, HUGO C, et al: Participation of glomerular endothelial cells in the capillary repair of glomerulonephritis. Am J Pathol 147:1715-1727, 1995
30. KIM YG, SUGA SI, KANG DH, et al: Vascular endothelial growth factor accelerates renal recovery in experimental thrombotic microangiopathy. Kidney Int 58:2390-2399, 2000
31. KANG DH, JOLY AH, OH SW, et al: Impaired angiogenesis in the remnant kidney model: I. Potential role of vascular endothelial growth factor and thrombospondin-1. J Am Soc Nephrol 12:1434-1447, 2001
32. SHWEIKI D, ITIN A, SOFFER D, KESHET E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843-845, 1992
33. PAULDING WR, CZYZYK-KRZESKA MF: Hypoxia-induced regulation of mRNA stability. Adv Exp Med Biol 475:111-121, 2000
34. LIU Y, COX SR, MORITA T, KOUREMBANAS S: Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ Res 77:638-643, 1995
35. IVAN M, KONDO K, YANG H, et al: HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science 292:464-468, 2001
36. YU F, WHITE SB, ZHAO Q, LEE FS: HIF-1alpha binding to VHL is regulated by stimulus sensitive proline hydroxylation. Proc Natl Acad Sci USA 98:9630-9635, 2001
37. MAXWELL PH, WIESENER MS, CHANG GW, et al: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275, 1999
38. COCKMAN ME, MASSON N, MOLE DR, et al: Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275:25733-25741, 2000
39. ARANY Z, HUANG LE, ECKNER R, et al: An essential role for p300/CBP in the cellular response to hypoxia. Proc Natl Acad Sci USA 93:12969-12973, 1996
40. LANDO D, PEET DJ, WHELAN DA, et al: Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295:858-861, 2002
41. LANDO D, PEET DJ, GORMAN JJ, et al: FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev 16:1466-1471, 2002
42. Meloni-EHRIG AM: Renal cancer: Cytogenetic and molecular genetic aspects. Am J Med Genet 115:164-172, 2002
43. ZENG H, DATTA K, NEID M, et al: Requirement of different signaling pathways mediated by insulin-like growth factor-I receptor for proliferation, invasion, and VPF/VEGF expression in a pancreatic carcinoma cell line. Biochem Biophys Res Commun 302:46-55, 2003
44. OLSON TA, MOHANRAJ D, CARSON LF, RAMAKRISHNAN S: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54:276-280, 1994
45. PAL S, DATTA K, KHOSRAVI-FAR R, MUKHOPADHYAY D: Role of protein kinase Czeta in Rasmediated transcriptional activation of vascular permeability factor/vascular endothelial growth factor expression. J Biol Chem 276:2395-2403, 2001
46. DELARUE F, VIRONE A, HAGEGE J, et al: Stable cell line of T-SV40 immortalized human glomerular visceral epithelial cells. Kidney Int 40:906-912, 1991
47. KRISHNAMURTI U, CHEN Y, MICHAEL A, et al: Integrin-mediated interactions between primary/T-sv40 immortalized human glomerular epithelial cells and type IV collagen. Lab Invest 74:650-657, 1996
48. SHIGETA M, SANZEN N, OZAWA M, et al: CD151 regulates epithelial cell-cell adhesion through PKC- and Cdc42-dependent actin cytoskeletal reorganization. J Cell Biol 163:165-176, 2003
49. ZHANG XA, BONTRAGER AL, HEMLER ME: Transmembrane-4 superfamily proteins associate with activated protein kinase C (PKC) and link PKC to specific beta(1) integrins. J Biol Chem 276:25005-25013, 2001
50. EIKMANS M, BAELDE JJ, DE HEER E, BRUIJN JA: ECM homeostasis in renal diseases: A genomic approach. J Pathol 200:526-536, 2003